| 1. |
Serino D, Santaone ME, Caputo D, et al. Febrile infection-related epilepsy syndrome (FIRES): prevalence, impact and management strategies. Neuropsychiatr Dis Treat, 2019, 15: 1897-1903.
|
| 2. |
van Baalen A, Hausler M, Boor R, et al. Febrile infection-related epilepsy syndrome (FIRES): a nonencephalitic encephalopathy in childhood. Epilepsia, 2010, 51(7): 1323-1328.
|
| 3. |
Gaspard N, Hirsch LJ, Sculier C, et al. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives. Epilepsia, 2018, 59(4): 745-752.
|
| 4. |
Kramer U, Chi CS, Lin KL, et al. Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. Epilepsia, 2011, 52(11): 1956-1965.
|
| 5. |
Sakuma H, Awaya Y, Shiomi M, et al. Acute encephalitis with refractory, repetitive partial seizures (AERRPS): a peculiar form of childhood encephalitis. Acta Neurol Scand, 2010, 121(4): 251-256.
|
| 6. |
Patil SB, Roy AG, VinayanKP. Clinical profile and treatment outcome of febrile infection-related epilepsy syndrome in South Indian children. Ann Indian Acad Neurol, 2016, 19(2): 188-194.
|
| 7. |
Fox K, Wells ME, Tennison M, et al. Febrile Infection-Related Epilepsy Syndrome (FIRES): A Literature Review and Case Study. The Neurodiagnostic Journal, 2017, 57(3): 224-233.
|
| 8. |
Rivas-Coppola MS, Shah N, Choudhri AF, et al. Chronological evolution of magnetic resonance imaging findings in children with febrile infection-related epilepsy syndrome. Pediatric Neurology, 2016, 55: 22-29.
|
| 9. |
Howell KB, Katanyuwong K, Mackay MT, et al. Long-term follow-up of febrile infection-related epilepsy syndrome. Epilepsia, 2012, 53(1): 101-110.
|
| 10. |
van Baalen A, Vezzani A, Hausler M, et al. Febrile infection-related epilepsy syndrome: Clinical review and hypotheses of epileptogenesis. Neuropediatrics, 2017, 48(1): 5-18.
|
| 11. |
Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain, 2011, 134(Pt 10): 2802-2818.
|
| 12. |
Nosadini M, Mohammad SS, Suppiej A, et al. Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome. Developmental medicine and child neurology, 2016, 58(11): 1180-1192.
|
| 13. |
Rogawski MA, Tofighy A, White HS, et al. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res, 2015, 110: 189-205.
|
| 14. |
洪震, 廖衛平, 孟紅梅, 等. 拉考沙胺添加治療中國部分性癲癇發作患者的療效和安全性:一項隨機雙盲試驗和開放標簽擴展試驗的亞組分析和事后分析. 中國臨床神經科學, 2019, 27(4): 361-378.
|
| 15. |
孫豐森, 張世鵬, 許述. 4 種抗癲癇新藥的研究和開發. 國際藥學研究, 2018, 45(11): 845-851.
|